Pharming Group (NASDAQ:PHAR) vs. Briacell Therap (NASDAQ:BCTX) Head-To-Head Survey

Briacell Therap (NASDAQ:BCTX) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Insider & Institutional Ownership

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Briacell Therap and Pharming Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Pharming Group	3.30%	4.64%	2.55%

Valuation & Earnings

This table compares Briacell Therap and Pharming Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31 million	($7.92)	-0.50
Pharming Group	$376.13 million	2.53	$2.85 million	$0.16	84.16

Pharming Group has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Briacell Therap and Pharming Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1	0	0	0	1.00
Pharming Group	1	1	3	0	2.40

Pharming Group has a consensus price target of $38.33, indicating a potential upside of 184.69%. Given Pharming Group’s stronger consensus rating and higher possible upside, analysts plainly believe Pharming Group is more favorable than Briacell Therap.

Risk & Volatility

Briacell Therap has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500.

Summary

Pharming Group beats Briacell Therap on 11 of the 13 factors compared between the two stocks.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.